All In Biotech

Drug Trial Radar · NCT02832375

Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity

A Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity

Last checked: Nov 20, 2026Latest source record: May 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 242 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

242

Actual

Start

Mar 1, 2016

Primary completion

May 1, 2016

Study completion May 12, 2016

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jul 14, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This single center, comparative design study will be used to investigate the efficacy of an experimental stannous fluoride containing dentifrice in relieving dentinal hypersensitivity (DH) after short term use compared with a standard fluoride dentifrice.

Conditions

  • Dentin Sensitivity

Interventions

  • stannous fluorideDrug

    0.454% w/w stannous fluoride containing 1100ppm of fluoride

  • sodium monofluorophosphateDrug

    0.76% w/w sodium monofluorophosphate containing 1000ppm fluoride

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Schiff Sensitivity Score on Day 3Time frame: Baseline, Day 3

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Las Vegas, Nevada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.